On Monday 9th November the method for the PTH assay at HEFT will change from the Roche assay to the Abbott Architect assay. Our comparisons have shown that the results from the Abbott method have a positive bias when compared against the Roche method so you should expect to see slightly higher results. We are therefore going to dual report PTH results for a period to allow transition of serially monitored patients and to establish new PTH baselines.
New Reference Interval (Abbott): 1.6 – 7.2 pmol/L
Previous Reference Interval (Roche): 1.6 - 6.9 pmol/L
Note: there is no change to specimen handling instructions. EDTA plasma is still the recommended sample type. If you have any queries or comments please contact Craig Webster (Clinical Lead for Blood Sciences) by email or the Duty Biochemist on Bleep 2506.
Note re accreditation status. This PTH assay is currently not on our UKAS accreditation scope.
Tests not appearing on this scope are either under consideration or in the process of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff. .